Gallium 68 tilmanocept - Navidea Biopharmaceuticals
Alternative Names: [68Ga]Ga-tilmanocept; Ga-68 tilmanocept; Gallium 68 labelled tilmanocept - Navidea BiopharmaceuticalsLatest Information Update: 28 Sep 2023
At a glance
- Originator Navidea Biopharmaceuticals; University of Alabama at Birmingham
- Developer Navidea Biopharmaceuticals; University Medical Center Utrecht; University of Alabama at Birmingham
- Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Thyroid cancer
- No development reported Atherosclerosis
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Atherosclerosis(Diagnosis) in USA
- 19 Apr 2022 Navidea Biopharmaceuticals receives a decision of grant for patent application covering targeted delivery of payloads attached to the Manocept platform in Japan
- 29 Nov 2021 Phase-III clinical trials in Thyroid cancer (Diagnosis) in Netherlands (Intratumoural) (EudraCT2021-002470-42)